

Special Issue

Design and Fabrication of Theranostic Nanoparticles

Message from the Guest Editors

Theranostics, defined as nanomedicine that combines diagnostics with therapeutics, employ personalized medicine for cancer treatment or other diseases, are designed to improve the detection, increase the efficacy of the treatment, and limit the associated systemic toxicity. The ideal theranostic agent should assemble the below criteria: - Safe to the organism;

- Stable under physiological conditions when delivered;
- Able to penetrate through any biological barrier encountered whole en route to the intended tissue or organ while also having no significant toxic side effects;
- Rapidly and selectively able to accumulate in target(s) of interest;
- Efficiently deliver a sufficient amount of the drug(s);
- Report biochemical and morphological characteristics of the disease(s);
- Be rapidly cleared from the body or biodegraded into nontoxic byproducts. This Special Issue is devoted to the field of theranostic selection from design and synthesis to in vitro and in vivo studies and up to a clinical applied solution based on a core technology that combines imaging, therapeutic drugs, and diagnostic labels into a single entity or multiple combinations of nanomedicine.

Guest Editors

Dr. Gianina Dodi

Faculty of Medical Bioengineering, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania

Prof. Dr. Abbas Rahdar

Department of Physics, Faculty of Science, University of Zabol, Zabol, Iran

Deadline for manuscript submissions

closed (30 June 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/126776

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).